Objectives: Substantial progress has been made in identifying how the treatment parameters used in electroconvulsive therapy (ECT) impact its cognitive side effects. However, there is limited information regarding the role of memory enhancers in post-ECT cognitive disturbances. We evaluated the therapeutic and prophylactic efficacy of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing ECT.
Methods: A triple blind (the study subjects, clinician assessing the cognition, and the data analyst were unaware of subject allocation for trial assessment) randomized controlled trial was carried out in a General Hospital Psychiatry Unit. Subjects were randomized into 2 groups. One group received ECT with placebo, whereas the other group received ECT and donepezil (a memory-enhancing drug). Study participants were assessed in post-ECT period to analyze cognitive deficits and to compare the differences in 2 groups, as regards recovery of various aspects of cognition.
Results: The post-ECT recovery of various components of cognition was more rapid in patients using donepezil as compared to those not given donepezil (P < 0.05).
Conclusions: This significant improvement in recovery time among patients receiving donepezil bears therapeutic implication in immediate post-ECT cognitive deficits.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.yct.0000230365.81368.2d | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study of the Pharmacological Activity Spectrum of the New Original NT-3 Mimetic Dipeptide GTS-302.
Dokl Biochem Biophys
January 2025
Center for Strategic Planning and Management of Biomedical Health Risks, Federal Medical and Biological Agency, Moscow, Russia.
Unlabelled: The association of the pathogenesis of neurodegenerative diseases, depression, anxiety, and cognitive disorders with neurotrophin-3 deficiency determines the prospect of creating drugs with a similar mechanism of action. Since the use of full-length NT-3 is limited by unsatisfactory pharmacokinetic properties, the creation of low-molecular mimetics of neurotrophin-3 that are active when administered systemically is relevant. The Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies has created a dimeric dipeptide mimetic of the 4th loop of NT-3, hexamethylenediamide bis-(N-γ-oxybutyryl-L-glutamyl-L-asparagine) with the laboratory code GTS-302, which activates TrkC and TrkB receptors.
View Article and Find Full Text PDFPotential of to mitigate epileptogenesis and cognitive dysfunction on kainate-induced post- model.
IBRO Neurosci Rep
June 2025
Department of Pharmacy, University of Mountains, P.O. Box 208, Bangangté, Cameroon.
Background And Aim: To date, there is no treatment to prevent the development of temporal lobe epilepsy, the most common form of drug-resistant epilepsy. A recent study revealed the antiepileptic-like effect of the aqueous extract of . Given the potential of this extract, the antiepileptogenic- and learning and memory-facilitating-like effects of the aqueous extract of were assessed using the kainate-induced post- model.
View Article and Find Full Text PDFHippocampal sharp-wave ripples and hippocampal-prefrontal synchrony regulate memory-enhancing effects of intranasal insulin in an STZ-induced Alzheimer's model.
Life Sci
November 2024
Neurobiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:
Aims: Alzheimer's disease is characterized by memory loss and pathological changes in the brain, such as amyloid beta and tau pathology, disruptions in neural circuits and neuronal oscillations are also significant indicators of this disease and potential therapeutic targets. We studied how intranasal insulin impacts memory and neural oscillations in an Alzheimer's disease rat model induced by STZ.
Main Methods: Male Wistar rats were intracerebroventricularly injected with STZ, followed by intranasal insulin therapy.
Retraction notice to "Neuroprotective and memory enhancing effects of auraptene in a rat model of vascular dementia: Experimental study and histopathological evaluation" [Neurosci. Lett. 623 (2016) 13-21].
Neurosci Lett
November 2024
Targeted Drug Delivery Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
Attenuation of age-related cognitive decline and memory deficits through apomorphine administration.
Pak J Pharm Sci
July 2024
Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan/Neuroscience Research Laboratory, Dr Panjwani Center for Molecular Medicine and Drug Research-ICCBS, University of Karachi, Karachi, Pakistan.
Oxidative stress, stemming from heightened production of reactive oxygen species and free radicals, significantly contributes to the aging process. Apomorphine emerges as a pivotal medication for managing Alzheimer's, Parkinson's and other age-related conditions. This study aims to explore the memory-enhancing and neuroprotective properties of apomorphine, utilizing male Albino Wistar rats aged 4 and 24 months as subjects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!